On 3 March 2009, NeuroSearch increased its share capital with the issue of
530,745 new shares of DKK 20 nominal value each at a price of DKK 187 per
share. The shares were issued to Eli Lilly and Company as part of a payment to
NeuroSearch relating to the signing of a new three-year drug discovery and
development alliance in February 2009.
Pursuant to section 6 of Executive Order no. 1273 of 16 December 2008 on
Issuers' Disclosure Obligations, it is hereby announced that at the end of
March 2009, the total nominal value of NeuroSearch A/S' share capital is DKK
325,480,600, which is made up of 16,274,030 shares with a nominal value of DKK
20 each, and corresponding to 325,480,600 votes.
Flemming Pedersen
CEO
Contact person:
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4017 5103
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The company's core business covers the development of novel
drugs, based on a broad and well-established drug discovery platform focusing
on ion channels and CNS dis-orders. A substantial share of NeuroSearch's
activities is partner financed through an alliance with Eli Lilly and Company
and collaborations with GlaxoSmithKline and Abbott. The drug pipeline comprises
seven clinical (Phase I-III) development programmes: ACR16 for Huntington's
disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for
ADHD (Phase II) in partnership with Abbott, ACR325 for Parkinson's disease
(Phase II ready), ACR343 for schizophrenia (Phase II ready), ABT-560 for the
treatment of various CNS disorders (Phase I) in collaboration with Abbott and
NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad
portfolio of preclinical drug candidates and holds equity interests in several
biotech companies.
